In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
Chenxi Jiang, M.P.H., from the American Cancer Society in Atlanta, and colleagues used data from the U.S. Cancer Statistics Database to compare differences in cervical cancer incidence rates for women ...
Researchers explain Care Coordination and Collaboration Programs in Oncology, which use patient navigators to ease disparities in cancer care for Native American patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results